Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and community-acquired pneumonia and skin structure infections.

Avarofloxacin demonstrates an antibacterial effect against numerous Gram-positive bacteria (mean MIC90: 0.12 mg/L) [2]. Avarofloxacin has the potential for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections [3].

878592-87-1

C21H23F2N3O4

419.42

JNJ-Q2;Avarofloxacin

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years